Faron Pharmaceuticals Limited (AIM:FARN) CEO Dr Juho Jalkanen talked with Proactive's Stephen about the significant fast-track designation awarded to their cancer immunotherapy, bexmarilimab, by the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This milestone aligns with prior FDA acknowledgments, marking critical progress in addressing relapsed refractory Myelodysplastic Syndrome (r/r MDS).
Faron also announced MHRA approval to expand its BEXMAB trial to UK sites.
Jalkanen explained, “UK is like a second home for us,” emphasising the importance of extending treatment access to UK patients. He also detailed how the Innovation Passport streamlines regulatory interactions, rolling submissions, and early drug access opportunities.
Looking ahead, Dr. Jalkanen shared that a confirmatory Phase 3 study is being planned for high-risk MDS patients globally, in collaboration with major regulatory authorities. The global trial underscores the company’s dedication to delivering groundbreaking therapies to patients in need.